Published in Open Respir Med J on February 22, 2013
The efficacy and safety of tigecycline for the treatment of bloodstream infections: a systematic review and meta-analysis. Ann Clin Microbiol Antimicrob (2017) 0.75
A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med (1997) 24.87
Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax (2003) 9.54
Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med (2001) 9.08
Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis (2000) 7.80
Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA (1996) 5.31
Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis (2003) 5.21
Guidelines for the management of adult lower respiratory tract infections. Eur Respir J (2005) 3.51
The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis (2005) 2.57
Reaching stability in community-acquired pneumonia: the effects of the severity of disease, treatment, and the characteristics of patients. Clin Infect Dis (2004) 2.37
The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis (2005) 2.33
Clinical practice. Management of community-acquired pneumonia. N Engl J Med (2002) 1.92
Severe community-acquired pneumonia. Risk factors and follow-up epidemiology. Am J Respir Crit Care Med (1999) 1.83
Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia. Diagn Microbiol Infect Dis (2008) 1.40
Early switch from intravenous to oral antibiotics and early hospital discharge: a prospective observational study of 200 consecutive patients with community-acquired pneumonia. Arch Intern Med (1999) 1.21
Guidelines for empiric antimicrobial prescribing in community-acquired pneumonia. Chest (2004) 1.17
Community-acquired pneumonia in patients with and without chronic obstructive pulmonary disease. J Infect (2009) 1.16
Escalation of antimicrobial resistance among Streptococcus pneumoniae: implications for therapy. Semin Respir Crit Care Med (2005) 1.05
Prognostic factors for serious morbidity and mortality from community-acquired lower respiratory tract infections among the elderly in primary care. Fam Pract (2005) 1.02
Clinical implications and treatment of multiresistant Streptococcus pneumoniae pneumonia. Clin Microbiol Infect (2006) 1.01
Tigecycline: a novel glycylcycline antibiotic. Expert Rev Anti Infect Ther (2006) 0.99
Staphylococcus aureus pneumonia: emergence of MRSA in the community. Semin Respir Crit Care Med (2005) 0.94
Predictors of mortality in the immunocompromised patient with pulmonary infiltrates. Arch Intern Med (1986) 0.91
Prior outpatient antibacterial therapy as prognostic factor for mortality in hospitalized pneumonia patients. Respir Med (2006) 0.85
[Prognostic factors and outcome of community-acquired pneumonia in hospitalized adult patients]. Rev Med Chil (2007) 0.77
Tigecycline for the treatment of infections due to resistant Gram-positive organisms. Expert Opin Investig Drugs (2006) 0.77
Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis (2010) 2.41
The 13-valent pneumococcal conjugate vaccine for invasive pneumococcal disease in Alaska native children: results of a clinical trial. Pediatr Infect Dis J (2013) 1.84
Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology (2003) 1.66
Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia. Diagn Microbiol Infect Dis (2008) 1.40
Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia. Antimicrob Agents Chemother (2013) 1.21
Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia. BMC Pulm Med (2009) 1.13
Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline. Antimicrob Agents Chemother (2011) 1.12
A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae. J Antimicrob Chemother (2008) 1.06
Pharmacokinetics and safety profile of tigecycline in children aged 8 to 11 years with selected serious infections: a multicenter, open-label, ascending-dose study. Clin Ther (2012) 0.91
Phase 3 trial evaluating the immunogenicity, safety, and tolerability of manufacturing scale 13-valent pneumococcal conjugate vaccine. Vaccine (2011) 0.76